Goldfarb

Netgain Announces $35 Million Investment from Summit Partners to Accelerate its Mission to Modernize Accounting

Retrieved on: 
Wednesday, April 3, 2024
Cloud, Goldfarb, Organization, Growth, Burnout, CFO, Accounting, NetSuite, News, Adam Nathan, Summit Partners

DENVER, April 3, 2024 /PRNewswire/ -- Netgain, a leading software provider for finance and accounting teams, today announced a $35 million minority investment led by global growth investor Summit Partners.

Key Points: 
  • DENVER, April 3, 2024 /PRNewswire/ -- Netgain, a leading software provider for finance and accounting teams, today announced a $35 million minority investment led by global growth investor Summit Partners.
  • Netgain was founded in 2018 with a mission to modernize the Office of the CFO.
  • The company's founders, Nathan Smart and Adam Riches, began their careers as auditors, controllers and finance managers, experiencing firsthand the technical and time-consuming challenges that accounting and finance professionals face.
  • The accounting industry is facing a significant talent exit , with declining enrollments at accounting programs and a record number of retirements.

Trialbee's Jamie Goldfarb to Lead Discussion on Defining Success and Enhancing Collaboration in Clinical Trials at Patients as Partners in Clinical Research Conference

Retrieved on: 
Thursday, March 14, 2024
Honey, Goldfarb, Patient, Success, Partner, Food and Drug Administration, ROI, Digital, TIL, Pharmacy, GSK, Research, Participation, National Cancer Institute, Cancer, Medidata Solutions, Ecosystem, Melanoma, Food, FDA, Process optimization, Fireside chats, Pharmaceutical industry

CHAPEL HILL, N.C. and MALMÖ, Sweden, March 14, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient recruitment for clinical trials, is honored that Director of Patient Recruitment Strategy Jamie Goldfarb will take center stage at the Patients as Partners in Clinical Research on March 20-22, in Philadelphia, PA.

Key Points: 
  • The session aims to strengthen relationships among sites, sponsors, and patients to deepen understanding and engagement.
  • "Many patients aren't aware that clinical trials present viable treatment opportunities, and if they do, their needs are often overlooked," Goldfarb said.
  • "By actively listening to patients, sponsors can gain invaluable insights and perspectives that lead to medical advances and improve countless lives."
  • The Patients as Partners in Clinical Research conference offers a unique opportunity to hear from pharmaceutical research and development leaders, Food and Drug Administration (FDA) representatives, and patient advocates on how patient involvement drives greater efficiencies in clinical research.

Avangrid Partners with Colby College to Launch Global Sustainability Independent-Study

Retrieved on: 
Friday, February 2, 2024
Environment, Other Energy, Utilities, Oil, Gas, Coal, Sustainability, Alternative Energy, Energy, University, Education, Partnership, Multimedia, Biophysical environment, College, Knowledge, ESG, Goldfarb, Interview, Consultant, Ethisphere Institute, AGR, Colby College, Climate change, Carbon, USA Today, Private sector, Massachusetts Institute of Technology, MBA, United, Iberdrola, Learning, Public policy, MIT, Student, Innovation, Workforce, Public affairs, Management

This first-of-its-kind program at Colby leverages Avangrid and Iberdrola’s ESG expertise to provide an immersive practical experience for students.

Key Points: 
  • This first-of-its-kind program at Colby leverages Avangrid and Iberdrola’s ESG expertise to provide an immersive practical experience for students.
  • View the full release here: https://www.businesswire.com/news/home/20240202806932/en/
    Colby students at Iberdrola’s offices in Bilbao, Spain (Photo: Business Wire)
    “As recognized sustainability leaders, it was a natural fit for Avangrid and Iberdrola to partner with Colby College to launch this unique course,” said Pedro Azagra, Avangrid CEO.
  • We need programs like this at an undergrad level to increase interest in the sustainability field and build ESG knowledge.
  • The course culminated in final presentations today to Colby faculty, fellow students, and Avangrid and Iberdrola experts.

SolarWinds Names Brian Goldfarb Chief Marketing Officer

Retrieved on: 
Tuesday, January 30, 2024
Security, Data Management, Other Technology, Technology, Software, SWI, Multimedia, Salesforce, Growth, Tenable, Database, Microsoft, Goldfarb, CMO, Cloud computing, SolarWinds, Marketing, Video game

SolarWinds (NYSE:SWI), a leading provider of simple, powerful, secure observability and IT management software, has named Brian Goldfarb as the company’s new Chief Marketing Officer (CMO).

Key Points: 
  • SolarWinds (NYSE:SWI), a leading provider of simple, powerful, secure observability and IT management software, has named Brian Goldfarb as the company’s new Chief Marketing Officer (CMO).
  • In this role, Goldfarb will oversee all aspects of global marketing efforts for SolarWinds and its world-class observability, database, and service management solutions.
  • “We are excited to welcome Brian as the newest member of the SolarWinds team, not only because of his track record in driving substantial, sustained growth but because he shares our vision and commitment to enriching the lives of customers,” said Sudhakar Ramakrishna, President and Chief Executive Officer, SolarWinds.
  • Earlier in his career, Goldfarb held product marketing and product management roles at Microsoft across developer tools and platforms, IT infrastructure systems, digital media, and cloud computing.

FONTAINEBLEAU MIAMI BEACH WELCOMES 2024 WITH ALL-STAR NEW YEAR'S EVE PERFORMANCES BY CARDI B AND GRYFFIN, PREMIUM DINING, AND FAMILY PARTY PACKAGES

Retrieved on: 
Monday, November 20, 2023
Cardi B, Glass, The Clark Family Experience, New Year's Eve, Mirabella, Heart, Friends, Goldfarb, Cardi, Family, Restaurant, Nightclub, Gryffin, Fontainebleau Miami Beach

MIAMI, Nov. 20, 2023 /PRNewswire/ -- Fontainebleau Miami Beach, the iconic luxury resort destination situated on 22 oceanfront acres in the heart of Miami Beach, along with BleauLive entertainment series, will welcome 2024 with one of South Florida's most anticipated New Year's Eve events – a night of high-octane live entertainment, premium dining and open bar packages, and a family experience that leaves no excuses for staying home. On Sunday, December 31, the iconic Cardi B will take the stage on the resort's legendary oceanfront poolscape, along with world-renowned DJ Gryffin, ringing in 2024 with a virtual ball drop and countdown as the champagne flows. The party continues by the pool through 2 a.m.

Key Points: 
  • The party continues by the pool through 2 a.m.
    "New Year's Eve is the ultimate celebration and Cardi B is the preeminent, crowd-pleasing performer," says Phil Goldfarb, Chief Operating Officer of Fontainebleau Development.
  • VIP Experience packages range from $5,000 to $35,000 and include a premium beverage package, and tableside service.
  • Fontainebleau Miami Beach is also offering a Family Experience that includes a buffet dinner (from 8 p.m. through 11 p.m.) and premium open bar for guests 21 and over.
  • The 9 p.m. seating at all three restaurants includes party favors and a midnight toast for a truly memorable celebration.

Trialbee's Jamie Goldfarb Earns Linnea Olson Award for Lifelong Advocacy Connecting Patients With Clinical Research

Retrieved on: 
Wednesday, November 8, 2023
Neoplasm, Imerman Angels, Medidata Solutions, Regenerative medicine, National Institutes of Health, Sheraton New York Times Square Hotel, NCI, ARM, Goldfarb, Life, Hope, Congress, Pancreas, Face, Liver, Patient, Research, TIL, Australian Melanoma Research Foundation, Friends, MRF, Euronext Paris, Disease, Clinical trial, Ecosystem, National Cancer Institute, NIH, Melanoma, Family, Cancer, MRA, Dassault Group, Bangladesh Technical Education Board, Nursing, Bank, Pharmaceutical industry, Medical imaging

CHAPEL HILL, N.C. and MALMO, Sweden, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Trialbee, the global team revolutionizing the patient recruitment ecosystem with technology, people, and passion, today announced Jamie Goldfarb, its Director of Patient Recruitment Strategy, was named the recipient of the 2023 Linnea Olson Award for lifelong achievements in patient advocacy.

Key Points: 
  • Goldfarb was diagnosed with melanoma for a third time in January 2011 — 11 weeks after giving birth to her son, Kai.
  • Throughout her experience, Goldfarb realized not all patients are aware of clinical research opportunities that may be available to them, especially in oncology.
  • I do it because a clinical trial saved my life, yet less than 5% of patients with cancer ever participate in clinical research.
  • Goldfarb accepted the Linnea Olson Award at the Medidata NEXT New York conference at the Sheraton New York Times Square Hotel on November 7.

Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms

Retrieved on: 
Monday, October 2, 2023
North American Menopause Society, Therapy, Progression-free survival, International Menopause Society, ESR1, ESMO, Life, Fulvestrant, Quality of life, Woman, NAMS, Mutation, Oncology, European Society for Medical Oncology, Goldfarb, Eli Lilly, Congress, Patient, Memorial Sloan Kettering Cancer Center, Annual general meeting, Diagnosis, Poster, AI, Menopause, Tamoxifen, Breast cancer, Birth control, Pharmaceutical industry, COLUMBUS

Prior adjuvant tamoxifen was associated with more severe vaginal/vulvar symptoms, as was a longer total duration of AI use in both adjuvant and metastatic settings.

Key Points: 
  • Prior adjuvant tamoxifen was associated with more severe vaginal/vulvar symptoms, as was a longer total duration of AI use in both adjuvant and metastatic settings.
  • Duration of prior AI in the adjuvant setting alone did not impact baseline vaginal or vulvar symptoms.
  • “As women are living longer with ER+ metastatic disease, it is extremely important to treat their symptoms to improve quality of life.
  • A secondary exploratory analysis showed numeric improvements in vaginal/vulvar symptoms with lasofoxifene versus fulvestrant (Goldfarb et al., 2023, ISSWSH).

Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system

Retrieved on: 
Thursday, December 15, 2022
Security (finance), Urology, Investigational device exemption, Nephrectomy, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duke University Hospital, Diagnosis, Adoption of electronic medical records in U.S. hospitals, Partnership, Hugo, Patient, Sale, Hospital, Swedish Health Services, NYSE, Disease, RAS, FDA, Pain, Sofie (surgical robot), Clinical trial, URO, Goldfarb, Safety, Gynaecology, Health, General surgery, Dentistry, Medical device, Medtronic, Expansion

DUBLIN, Dec. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital in Durham, N.C.

Key Points: 
  • "Robotic-assisted surgery provides many benefits within my specialty of urology, and I'm proud to have performed the first U.S. clinical trial case with the Medtronic Hugo RAS system."
  • The Expand URO clinical trial is being conducted pursuant to an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA).
  • "4
    The Hugo RAS system, combined with Touch Surgery Enterprise, offers a smart, digitally enabled surgical experience.
  • Regulatory requirements and status in individual countries and regions will determine market availability of the Hugo RAS system and approved indications.

HeartVista to Expand Beyond Heart MRIs, Changes Name to Vista.ai to Reflect Wider Focus

Retrieved on: 
Sunday, November 27, 2022
Harvard Medical School, Degenerative disease, FACC, Spine, CST, Statista, Radiological Society of North America, Guideline, Siemens Healthineers, CT, Algorithm, Heart, Khosla Ventures, Incidence, Magnetic resonance imaging, Hospital, Management of heart failure, Artificial intelligence, Patient, Heart failure, Workflow, Medicine, COVID, Trial of the century, FDA, CMR, COVID-19, Diagnosis, Anatomy, Myocarditis, Society for Medical Decision Making, Prostate, MRI, Brigham and Women's Hospital, Booth, Research, MPH, Small Business Innovation Research, Acquisition, Software, RSNA, Cleveland Clinic, Complex, GE Healthcare, Annual general meeting, Pericarditis, Goldfarb, Medical imaging, Medical device, MD

CHICAGO, Nov. 27, 2022 /PRNewswire/ -- HeartVista, a pioneer and leader in automated MRI solutions, today announced that it has changed its name to Vista.ai as the company broadens its sights to simplify and enhance MRI exams for anatomies beyond the heart. A major academic medical center has already begun a clinical study to evaluate the software for use with the prostate, and Vista.ai plans to launch a similar study for musculoskeletal scans in the near future. The company made the announcement from the Radiological Society of North America (RSNA) 108th Scientific Assembly and Annual Meeting held Nov. 27-Dec. 1, 2022, in Chicago.

Key Points: 
  • The company initially targeted cardiac MRI (CMR) as it is increasingly considered the gold-standard cardiac diagnostici, yetthe heart is a notoriously difficult and time-consuming anatomy to scan.
  • Vista.ai is demonstrating One Click MRI this week at Booth 5143 in the AI Showcase during RSNA exhibit hours.
  • Dr. Kwong will present at noon CST, Monday, Nov. 28, 2022, in the RSNA AI Theater (#5149).
  • Vista.ai developed One Click MRI using sophisticated and versatile AI-based algorithms that would be scalable to other types of MRI scans.

Melio Appoints Sivanne Goldfarb as Vice President of Risk, Credit & Data Products

Retrieved on: 
Wednesday, May 18, 2022
Small business, PayPal, Risk management, Consumer's risk, Multimedia, Science and technology in Asia, Data science, Workflow, Meta, Compliance, CTO, Credit, Goldfarb, Heart, Research and development, Financial technology, Dataproducts, Management, Online shopping, Risk, Fraud, Melio Bettina

NEW YORK, May 18, 2022 /PRNewswire/ -- Melio, a leading B2B payments platform for small businesses, today announced the appointment of Sivanne Goldfarb as Vice President of Risk, Credit & Data Products. The appointment marks the latest addition to Melio's executive leadership as the company grows its product offerings and continues its rapid scaling.

Key Points: 
  • NEW YORK, May 18, 2022 /PRNewswire/ -- Melio , a leading B2B payments platform for small businesses, today announced the appointment of Sivanne Goldfarb as Vice President of Risk, Credit & Data Products.
  • Goldfarb joins Melio with over a decade of experience in product development, fintech, and risk management.
  • Most recently, she was the Director of Data Science & Data Engineering, Fraud, and Compliance at Meta FinTech, Meta's payments unit.
  • Goldfarb's appointment follows several other senior executives who joined Melio in recent months, including Chief Operating Officer Tomer Barel and Vice President of Research & Development Guy Zipori.